Filing Flows › Comparisons › RIGL vs LGND
Rigel Pharmaceuticals vs Ligand Pharmaceuticals: RIGL and LGND compared
Rigel Pharmaceuticals is the larger company: $80.9M of revenue in its latest quarter (Q3 2026) against $78.7M for Ligand Pharmaceuticals (Q3 2026). Rigel Pharmaceuticals is growing faster (+16% against -32% a year earlier). Rigel Pharmaceuticals is more profitable, with an operating margin of 21.1% against -20.0%.
Where the money goes: RIGL and LGND
Rigel Pharmaceuticals (RIGL) · Q3 2026
Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%, net earnings $13.2M, operating cash flow $34.6M. The chart follows the revenue to costs, profit and cash.
Ligand Pharmaceuticals (LGND) · Q3 2026
Ligand Pharmaceuticals, Q3 2026: revenue $78.7M (-32% year over year), operating margin -20.0%, net loss $28.5M, operating cash flow −$27.6M. The chart follows the revenue to costs, profit and cash.
| Rigel Pharmaceuticals (RIGL) | Ligand Pharmaceuticals (LGND) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $80.9M | $78.7M |
| Revenue growth, Y/Y | +16% | -32% |
| Operating margin | 21.1% | -20.0% |
| Net earnings | $13.2M | −$28.5M |
| Net margin | 16.3% | -36.2% |
| Operating cash flow | $34.6M | −$27.6M |
Where the revenue comes from
Rigel Pharmaceuticals
- Product sales, net: $72.3M (89%)
- Contract revenues from collaborations and other: $8.6M (11%)
Ligand Pharmaceuticals
- Revenue from intangible royalty assets: $47.2M (60%)
- Ojemda: $7.0M (9%)
- Other: $6.7M (8%)
- Capvaxive: $3.8M (5%)
Questions
Which is bigger, Rigel Pharmaceuticals or Ligand Pharmaceuticals?
Rigel Pharmaceuticals is the larger company: $80.9M of revenue in its latest quarter (Q3 2026) against $78.7M for Ligand Pharmaceuticals (Q3 2026).
Is Rigel Pharmaceuticals or Ligand Pharmaceuticals growing faster?
Rigel Pharmaceuticals is growing faster (+16% against -32% a year earlier).
Which is more profitable, Rigel Pharmaceuticals or Ligand Pharmaceuticals?
Rigel Pharmaceuticals is more profitable, with an operating margin of 21.1% against -20.0%.
More: Rigel Pharmaceuticals earnings · how Rigel Pharmaceuticals makes money · Ligand Pharmaceuticals earnings · how Ligand Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Oct 30, 2026). Fiscal quarters can end on different dates. Not investment advice.